EMA: Possible Link Between Very Rare Cases of Unusual blood Clots and Janssen Vaccine
European Medical Agency safety committee (PRAC) concluded that a warning about unusual blood clots with low blood platelets should be added to the product information for COVID-19 Vaccine Janssen. PRAC also concluded that these events should be listed as very rare side effects of the vaccine.
In reaching its conclusion, the Committee took into consideration all currently available evidence including eight reports from the United States of serious cases of unusual blood clots associated with low levels of blood platelets, one of which had a fatal outcome. As of 13 April 2021, over 7 million people had received Janssen’s vaccine in the United States.
All cases occurred in people under 60 years of age within three weeks after vaccination, the majority in women. Based on the currently available evidence, specific risk factors have not been confirmed.
PRAC noted that the blood clots occurred mostly at unusual sites such as in veins in the brain (cerebral venous sinus thrombosis, CVST) and the abdomen (splanchnic vein thrombosis) and in arteries, together with low levels of blood platelets and sometimes bleeding. The cases reviewed were very similar to the cases that occurred with the COVID-19 vaccine developed by AstraZeneca, Vaxzevria.
Healthcare professionals and people who will receive the vaccine should be aware of the possibility of very rare cases of blood clots combined with low levels of blood platelets occurring within three weeks of vaccination.
COVID-19 is associated with a risk of hospitalisation and death. The reported combination of blood clots and low blood platelets is very rare, and the overall benefits of COVID-19 Vaccine Janssen in preventing COVID-19 outweigh the risks of side effects.
EMA’s scientific assessment underpins the safe and effective use of COVID-19 vaccines. Use of the vaccine during vaccination campaigns at national level will take into account the pandemic situation and vaccine availability in individual Member States.
One plausible explanation for the combination of blood clots and low blood platelets is an immune response, leading to a condition similar to one seen sometimes in patients treated with heparin called heparin induced thrombocytopenia, or HIT.
EMA will continue to monitor the vaccine’s safety and effectiveness and provide the public with the latest information.
We need your support so Novinite.com can keep delivering news and information about Bulgaria! Thank you!
- » Covid-19 in Bulgaria: 123 New Cases
- » Chief Health Inspector Kunchev: High Mortality Rate from Covid-19 in Bulgaria Must Be Analysed
- » Bulgaria’s Chief Health Inspector Alerts to Insufficient Vaccination Rate
- » Covid-19 in Bulgaria: 100 Newly Infected, 15 Fatalities
- » Bulgarian Ombudsperson: 100,000 Bulgarians Cannot Obtain EU Covid-19 Certificates
- » Bulgaria: 208 New COVID-19 Infections